Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 172c; offers guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $246.81 -0.31%
EPS Growth %: -20.5%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -20.5%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $6.34, $1.72 better than the analyst estimate of $4.62. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $981.08 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2026 revenue of $4.25-4.5 billion, versus the consensus of $4.453 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Motilal Oswal Securities Starts V2 Retail Ltd (VREL:IN) at Buy
- JPMorgan Reiterates Overweight Rating on Legrand SA (LR:FP) (LGRDY) and Places on Positive Catalyst Watch
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
